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Abstract
Background—Urinary porphyrins are diagnostic of various metabolic disorders and xenobiotic
exposures, but comprehensive normative data for urinary porphyrin concentrations in children are
currently unavailable.
Methods—Subjects were participants in a prospective, randomized, controlled clinical trial of
dental materials safety, 8 to 12 y at inception, who were followed longitudinally for 7 y after baseline
with an extensive battery of neurobehavioral, neurological, renal function and urinary porphyrin
assessments. Porphyrins were quantified by HPLC. Linear regression analyses were used to measure
associations of porphyrin levels with age and gender.
Results—Mean concentrations, 95% confidence intervals, and 10th 50th, and 90th percentiles for
all 5 typically excreted urinary porphyrins are presented by year of age and by gender. Unadjusted
urinary concentrations (µg/l) of all 5 porphyrins remained relatively constant throughout the age
range of 8–18 y for both males and females. In contrast, creatinine-adjusted urinary porphyrin
concentrations (µg/g) declined significantly throughout this age range in both genders. Boys had
significantly higher pentacarboxyl- and copro- porphyrin levels compared with girls both before and
after creatinine adjustment.
Conclusions—Normative longitudinal data provided herein may facilitate the clinical assessment
of pediatric metabolic disorders and may be of particular relevance in evaluating porphyrin changes
as a biological indicator of disease or xenobiotic exposures among children and adolescents.
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INTRODUCTION
Porphyrins are formed as intermediates in the biosynthesis of heme, a process that takes place
in essentially all eukaryotic tissues. In humans and other mammals, porphyrins with 8,7,6,5,
and 4 carboxylated side chains (uro-, heptacarboxyl-, hexacarboxyl-, pentacarboxyl-, and
copro- porphryins) are commonly formed in excess of that required for heme synthesis and are
excreted in the urine and/or feces in established concentration ranges [1,2]. Urinary porphyrin
excretion may be abnormally elevated in a number of disease states including the inherited
porphyrias [3,4], certain liver and kidney diseases [5,6], and disorders of hemoglobin synthesis
[7]. Abnormal porphyrin excretion has also been documented in response to a variety of drugs
[8] and environmental chemical exposures, particularly, organochlorine compounds [9,10] and
heavy metals such as lead [11], arsenic [12,13], and mercury [14,15]. In each case, the specific
changes in porphyrin excretion patterns are potentially useful as diagnostic indicators of
ensuing, existing or remitting disease or chemical toxicity [16–19].
The efficacy of altered urinary porphyrin concentrations and excretion patterns as biomarkers
of disease or toxicant exposure is contingent upon the availability of established normal
reference values, which can vary by both age and gender. Whereas urinary porphyrin
concentrations are well established for adult human subjects [1,2,15], normative values of
urinary porphyrins for developmentally healthy children and adolescents are not available.
MATERIALS AND METHODS
The Study Population
The children’s cohort was derived from the recently completed Casa Pia clinical trial of the
health effects of dental amalgam fillings in children [20]. Subjects (n=507) were boys and girls
(54:46%), 70% white, aged 8–12 y at inception, who were residents of the Casa Pia school
system in Lisbon, Portugal. All subjects who participated in the clinical trial from which the
data reported herein were recruited were residents of the same boarding school throughout all
years of the trial. As such, they received the same diet and were comparable in all other social
respects. Eligibility requirements precluded children with preexisting neurological or
developmental disabilities, dental amalgam tooth fillings or blood lead levels ≥10 (µg/dl.
Subjects were initially randomized to mercury amalgam (treatment) or composite resin
(control) dental treatment groups. Because amalgam treatment is suspected to impact urinary
porphyrin profiles [21], only subjects receiving composite resin fillings (controls, n = 254)
were included in the present assessment of normative porphyrin levels. Children were
evaluated at baseline and at 7 subsequent annual intervals after initial dental treatment with an
extensive battery of neurobehavioral, neurological, renal function and urinary porphyrin
assessments. Follow-up data were obtained on a similar number of subjects in each treatment
group. The study protocol was approved by the institutional review boards at the University
of Washington and the University of Lisbon. All parents or guardians gave written consent,
and all children provided signed assent. Principal design and analytical issues involved in this
trial [22] as well as principal outcome measures [20] have been reported.
Procedures for urine collection and measurement of urinary porphyrins and creatinine
A urine sample (∼50 ml) was collected from each child at baseline and at each subsequently
scheduled annual visit to the University of Lisbon School of Dental Medicine for dental,
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neurological and neurobehavioral evaluations. Immediately following urine collection, a 10
ml aliquot was removed and acidified with 1 mol/l HCl for use in mercury analysis by
continuous flow, cold vapor spectrofluorometry [23]. Porphyrins were quantified in the
remaining unacidified portion of the urine sample by high performance liquid chromatography,
as previously described [24]. Urinary creatinine concentrations were also measured in
unacidified urine using a standard colorimetric procedure (Sigma, St. Louis, MO).
Statistical analyses
We used separate linear regression models for each porphyrin to test whether gender and age
were associated with average urinary porphyrin concentration (µg/l) during the study among
the composite group. We also tested for age and gender associations with average creatinine
adjusted urinary porphyrin levels (µg/g). We tested for age effects separately for each gender.
Robust standard errors were used to account for possible within-child correlation and
heteroskedasticity (variances increased with increasing mean value).
RESULTS
Table 1 presents demographic characteristics at baseline (BL) and at each year of follow-up
for all subjects in the composite (control) group for whom porphyrin assay results were
available. Subjects at baseline ranged in age from 8 to 12 y, mean 10 y. Table 2 presents
distributions (10th, 50th, 90th percentiles), mean values, and 95% confidence intervals for the
mean values of unadjusted concentrations (µg/l) of individual and total urinary porphyrins by
gender and age for children from ages 8–18 y. As shown, unadjusted porphyrin concentrations
remain relatively constant throughout the age range of 8 to 18 y for both genders. Notably,
however, boys have significantly (p < 0.05) higher unadjusted pentacarboxyl- and copro-
porphyrin concentrations than girls throughout this age range.
Table 3 presents distributions (10th, 50th, 90th percentiles), mean values, and 95% confidence
intervals for mean values of creatinine-adjusted concentrations (µg/g) of individual and total
urinary porphyrins by gender and age for children from ages 8–18 y. As shown, creatinine-
adjusted porphyrin concentrations decline significantly (p < 0.0001) throughout this age range
in both genders. Boys again were seen to have significantly (p<0.05) higher creatinine-adjusted
pentacarboxyl- and copro- porphyrin levels compared with girls. Additionally, blacks were
found to have significantly lower creatinine-adjusted (but not unadjusted) urinary porphyrin
levels than whites at all ages. This finding is attributed to significantly higher creatinine
excretion among blacks [25].
Table 4 presents individual porphyrin concentrations as a percentage of total porphyrins for
each age and gender. Va lues represent the percent of total urinary porphyrin concentration for
each individual porphyrin. Table 5 presents mean creatinine concentrations (g/l) for each age
and gender. Values increased by a comparable amount in both boys and girls over the age range
of 8 to15 y, then become relatively stable throughout the remaining 3 y of follow up to age 18
y. No significant differences in creatinine excretion between boys and girls were found. A
comprehensive report of longitudinal creatinine excretion values [25] in this subject population
is published.
DISCUSSION
An important data gap exists for normative urinary porphyrin concentrations for children and
adolescents. Bloom et al. [26] described total urinary porphyrin and creatinine values as
functions of age and sex among children aged from 9 months to 18 y. These observations are
of limited diagnostic value, however, since urinary concentrations for individual porphyrins
were not provided. More recently, Sunyer et al. [10] employed linear regression analysis to
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evaluate potential changes in urinary porphyrin excretion in relation to organochlorine
compound exposure among 4 y-old children. However, no normative values for urinary
porphyrin levels for children of this age were reported. In other studies, Ahmed [27] described
biochemical abnormalities in childhood porphyrias, but no normative urinary porphyrin data
were provided. Age-dependent reference values for urinary porphyrins among children aged
from 0.5 to 15 y were reported by Minder et al. [28]; however, these assessments were restricted
only to uro- and copro- porphyrin levels. Isomers of individual porphyrins, which may be of
importance in the evaluation of certain diseases or disorders, were not evaluated in the present
study.
Of note from the present findings is the observation that total urinary porphyrin concentrations
are higher in pre-adolescent children of both sexes and decline to reported adult ranges [1,2,
15,29] only by the late teen years. Although absolute concentrations of coproporphyrin appear
to contribute most substantially to higher porphyrin levels observed in younger children (Table
2 and Table 3), it is notable that the proportion of total porphyrin attributable to coproporphyrin
increases somewhat from ages 8 through 18 y, whereas the proportion of total porphyrin
attributable to uroporphyrin decreases by as much as 2-fold over this age range (Table 4). These
findings accentuate the importance of evaluating porphyrin alterations in children in relation
to mean porphyrin values for healthy children of the same age, rather than in relation to adult
reference values. Also of note is the observation that boys had significantly higher unadjusted
urinary concentrations of pentacarboxyl- and copro- porphyrins than girls throughout much of
the 8–18 age range. This difference was retained following creatinine adjustment (Table 3),
consistent with finding that urinary creatinine levels did not differ significantly between males
and females throughout the course of the study (Table 5). Similar finding were reported by
Bloom et al. [26], in which total creatinine-adjusted urinary porphyrin concentrations in boys
aged 9–18 y were higher than those seen in similarly aged girls. The mechanisms and possible
biological significance of this gender distinction remain to be determined. Notably, sex
hormones have been reported to influence porphyrin metabolism [30], possibly accounting for
this difference.
Also of considerable importance from the present findings is the importance of creatinine
adjustment when evaluating porphyrin changes among children of any age, owing to the
significant increase in creatinine excretion that occurs throughout late childhood and
adolescence. In the present population, urinary creatinine excretion increased over 2-fold from
0.68 g/l to 1.44 g/l between ages 8 and 18 y. These findings are of particular relevance when
evaluating porphyrin changes as a biological indicator of disease or disorder among younger
children, whose creatinine-adjusted porphyrin levels are likely to differ significantly from those
of teen-aged subjects or adults. For comparisons of children of similar age, creatinine-
adjustment offers the additional advantage in facilitating interpretation of porphyrin changes
in random (“spot”) or incompletely collected 24-h urine samples from children who are unable
to provide complete 24-h urine specimens.
In conclusion, this study provides comprehensive normative values for urinary concentrations
and ranges for 5 typically excreted porphyrins in healthy children between the ages of 8 and
18 y. These data may facilitate the clinical assessment of pediatric metabolic disorders and
may be of particular relevance in evaluating porphyrin changes as a biological indicator of
disease or xenobiotic exposure among children and adolescents.
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